interview
interview
The challenges of SynBio - by Zachary Karl, PhD
“Some of the challenges in SynBio, are the costs and the timelines. Timeline-wise, it takes a...
investors
NCT: Damien on 4 grams of NCT with over 99%...
🔬 Biomanufacturing breakthrough detailed: 4 grams of NCT produced at a 96% yield and with a...
investors
NCT: From concept to gram-scale quantity in...
🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone...
interview
Slack Capital interview: Chris Marlett,...
Last week, Slack Capital - an Australian investment research publication - released an investment...
interview
Slack Capital interview: Chris Marlett,...
Last week, Slack Capital - an Australian investment research publication - released an investment...
investors
Slack Capital interview: Damien Perriman, CCO
Last week, Slack Capital - an Australian investment research publication - has released an...
investors
Slack Capital interview: Damien Perriman, CCO...
Last week, Slack Capital - an Australian investment research publication - has released an...
investors
Slack Capital interview: Tyler Korman, VP of...
This week, Slack Capital - an Australian investment research publication - has released an...
interview
Slack Capital interview: Michael Heltzen, CEO
Today, Slack Capital - an Australian investment research publication - has released an investment...
interview
Slack Capital interview: Michael Heltzen, CEO...
Today, Slack Capital - an Australian investment research publication - has released an investment...
investors
AI transforming biotechnology: From form with...
Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states: "The Large Language...